Drug Profile


Alternative Names: CC-220; Iberdomide hydrochloride

Latest Information Update: 22 Jun 2017

Price : $50

At a glance

  • Originator Celgene Corporation
  • Class Anti-inflammatories; Antineoplastics; Isoindoles; Piperidones; Skin disorder therapies; Small molecules
  • Mechanism of Action CRBN protein inhibitors; Immunomodulators; Transcription factor modulators; Ubiquitin protein ligase complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • Phase I/II Multiple myeloma
  • Discontinued Cutaneous lupus erythematosus; Haematological malignancies; Sarcoidosis; Systemic scleroderma

Most Recent Events

  • 14 Jun 2017 Efficacy and adverse events data from a phase IIa trial in Systemic lupus erythematosus presented at the Annual European Congress of Rheumatology (EULAR-2017)
  • 04 May 2017 Celgene plans a phase I trial in healthy volunteers (NCT03135509)
  • 27 Apr 2017 Celgene plans a phase IIb trial in Systemic lupus erythematosus in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top